OncoMatch/Clinical Trials/NCT06320990
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
Is NCT06320990 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Tamoxifen 20mg for pancreatic cyst.
Treatment: Tamoxifen 20mg — Pancreatic mucinous cystic neoplasm (MCN) is a precursor to invasive pancreatic adenocarcinoma which occurs almost exclusively in females in their 5th-7th decade. Currently the only option for MCN treatment and prevention of invasive pancreatic ductal adenocarcinoma (PDA) is oncologic resection. The clinical features of pancreatic MCN support the influence of sex hormones in the pathogenesis of the disease. Anti-hormonal therapy may therefore constitute an effective approach to treatment. Preliminary analyses from preclinical studies suggest that tamoxifen inhibits the spread and normal life cycle in MCN epithelial cells and fibroblasts. Investigators hypothesize that in humans, treatment with tamoxifen will lead to cyst regression or stabilization and may spare or delay the need for resection. Up to 15 participants not undergoing immediate resection will be enrolled and take tamoxifen orally for up to 24 weeks. The study will assess the feasibility of tamoxifen as a treatment for pancreatic MCN.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: estrogen antagonist (tamoxifen, clomifene, raloxifene, fulvestrant, anastrazole)
Exception: subjects who have previously used an estrogen antagonist are eligible provided the last use was at least 5 years prior to enrollment
Current or prior use of tamoxifen or another estrogen antagonist including, but not limited to, clomifene, raloxifene, fulvestrant, anastrazole; subjects who have previously used an estrogen antagonist are eligible provided the last use was at least 5 years prior to enrollment.
Lab requirements
Kidney function
egfr > 30ml/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify